The United Bio-technology (Hengqin) Co., Ltd has officially obtained ISO 27001 Information Security Management System certification, marking that the Company’s information security management has reached internationally recognized standards. This milestone establishes a robust security foundation for global market expansion, strengthens trust with partners, and safeguards the implementation of innovative business initiatives.

As one of the most core and authoritative standards in the global information security domain, ISO 27001 focuses on the confidentiality, integrity and availability of information assets. Its certification process involves rigorous, multi-dimensional assessments, including risk evaluation, system establishment, organization-wide implementation and independent third-party audits. For the pharmaceutical industry, information security extends beyond the protection of R&D data and proprietary manufacturing know-how. It is also directly linked to the safeguarding of patient privacy and the security of drug quality traceability systems, making it a fundamental cornerstone of compliant operations and brand trust.

From the launch of the system development to the successful certification, United Bio-tech completed the entire process within six months. A dedicated project team led by senior management was established, involving all departments across R&D and corporate functions. The team carried out a comprehensive series of tasks, including information asset identification, risk assessment, policy and procedure development, information security training, internal audits and mock audits. Upholding a “high standards, strict requirements” approach, the Company advanced both system implementation and certification with rigor and efficiency.

The successful attainment of ISO 27001 certification is not an endpoint, but a new starting point for information security management. Going forward, United Bio-tech will continue to benchmark against international standards and dynamically enhance its information security framework, providing stronger safeguards for accelerated new drug R&D, pharmaceutical quality control and industry chain collaboration. Through compliance and security, the Company will empower the high-quality development of its pharmaceutical business.